A Phase 2/3 interventional study of Pramipexole Immediate Release and Pramipexole Extended Release in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 19 sites in Japan. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2014-07-31.
Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 20th largest by enrollment, is one of 5 that started in 2007, is the only one in phase 2/3, and was the 12th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2007, is the only one in phase 2/3, and was the 14th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD on levodopa (L-DOPA) therapy (the double-blind period). The double-blind period will be followed by the open-label 52 week administration of pramipexole ER to evaluate the long term safety and efficacy (the open-label period).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who exhibit any therapeutically problematic issues or status based on L-DOPA therapy:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -\> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
Drug: Pramipexole Extended Release
patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -\> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
Drug: Pramipexole Immediate Release
titrated as individually needed (0.25 mg - 4.5 mg daily)
titration as individually needed (0.375 mg -4.5 mg daily)
Percentage of Participants Who Experienced Adverse Events
An adverse event is defined as any untoward medical occurrence
Time frame: 12 weeks
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score
UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: baseline and after 12 weeks treatment
Change From Baseline in Percentage Off-time
Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
Time frame: baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia
Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia
Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia
Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time With Troublesome Dyskinesia
Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 12 weeks treatment
Responder Rate For Clinical Global Impression of Improvement (CGI-I)
CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)
Time frame: baseline and after 12 weeks treatment
Responder Rate For Patient Global Impression of Improvement (PGI-I)
PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring of 1 or 2 (at least much better)
Time frame: baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part I Score
UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood
Time frame: baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part II Score
UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.
Time frame: baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part III Score
UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms
Time frame: baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part IV Score
UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy
Time frame: baseline and after 12 weeks treatment
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement)
Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse
Time frame: baseline and after 12 weeks treatment
Change From Baseline in L-dopa Daily Dose
The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.
Time frame: baseline and after 12 weeks treatment
Trough Plasma Concentration at Steady State
Geometric mean (gMean) was calculated for trough plasma concentrations of pramipexole at steady state after administration of pramipexole IR 4.5mg and pramipexole ER 4.5mg.
Time frame: at Visit 8 after pramipexole ER 4.5mg and IR 4.5mg treatment
Dose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment
Dose proportionality of trough plasma concentrations at steady state is explored by using the power model that described the functional relationship between the dose and plasma concentration
Time frame: from Visit 1 to Visit 8 after pramipexole ER
Change From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase)
UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms. Least square means and standard errors presented are from ANCOVA with factors treatment and covariate baseline.
Time frame: Week 12 to Week 16
Percentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase)
Percentage of patients with no worsening of UPDRS Parts II+III Total Score by more than 15% from week 12 to week 16 (Open-label: Dose Adjustment Phase)
Time frame: Week 12 to Week 16
Clinical Global Impression of Improvement (CGI-I) at Week 16 Compared to Patient's CGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)
Clinical Global Impression of Improvement (CGI-I) at week 16 compared to patient's CGI-I status at week 12. CGI-I scores ranging from '1' (very much improved) to '7' (very much worse)
Time frame: Week 12 to Week 16
Patient Global Impression of Improvement (PGI-I) at Week 16 Compared to Patient's PGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)
Patient Global Impression of Improvement (PGI-I) at week 16 compared to patient's PGI-I status at week 12. PGI-I scores ranging from '1' (very much better) to '7' (very much worse).
Time frame: Week 12 to Week 16
Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase)
UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: Baseline and after 64 weeks treatment
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase)
Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse
Time frame: baseline and after 64 weeks treatment
Change From Baseline in Percentage Off-time (Open-label: Maintenance Phase)
Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
Time frame: baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase)
Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase)
Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase)
Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase)
Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and after 64 weeks treatment
Change From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase)
The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.
Time frame: baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase)
UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood
Time frame: baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase)
UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.
Time frame: baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase)
UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms
Time frame: baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase)
UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy
Time frame: baseline and after 64 weeks treatment
| Milestone | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Started | 56 | 56 |
| Completed | 51 | 53 |
| Not completed | 5 | 3 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Started | 51 | 53 |
| Completed | 43 | 42 |
| Not completed | 8 | 11 |
| Withdrew: Adverse event | 6 | 6 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Other reason - investigator's judgement | 1 | 1 |
UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| UPDRS scores on a scale | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score | -13.6 ± 1.3 | -13.3 ± 1.3 |
Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
| Percentage of off-time | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in Percentage Off-time | -5.8 ± 2.4 | -7.8 ± 2.4 |
Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in Percentage On-time Without Dyskinesia | 6.4 ± 2.5 | 7.0 ± 2.5 |
Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia | -0.4 ± 0.4 | 0.1 ± 0.4 |
Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia | 6.0 ± 2.5 | 7.1 ± 2.5 |
Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in Percentage On-time With Troublesome Dyskinesia | -0.1 ± 0.5 | 0.5 ± 0.5 |
CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)
| percentage of participants | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Responder Rate For Clinical Global Impression of Improvement (CGI-I) | 48.2 | 50.0 |
PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring of 1 or 2 (at least much better)
| percentage of participants | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Responder Rate For Patient Global Impression of Improvement (PGI-I) | 33.9 | 33.9 |
UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood
| UPDRS scores on a scale | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in UPDRS Part I Score | 0.1 ± 0.2 | -0.2 ± 0.2 |
UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.
| UPDRS scores on a scale | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in UPDRS Part II Score | -3.3 ± 0.4 | -3.4 ± 0.4 |
UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms
| UPDRS scores on a scale | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in UPDRS Part III Score | -10.2 ± 1.0 | -9.9 ± 1.0 |
UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy
| UPDRS scores on a scale | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in UPDRS Part IV Score | -0.2 ± 0.2 | -0.4 ± 0.2 |
Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse
| percentage of participants | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) | 78.6 | 82.1 |
The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.
| mg per day | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Change From Baseline in L-dopa Daily Dose | -5.3 ± 3.0 | -1.8 ± 3.0 |
An adverse event is defined as any untoward medical occurrence
| percentage of participants | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Percentage of Participants Who Experienced Adverse Events | 83.93 | 83.93 |
Geometric mean (gMean) was calculated for trough plasma concentrations of pramipexole at steady state after administration of pramipexole IR 4.5mg and pramipexole ER 4.5mg.
| ng/ml | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| Trough Plasma Concentration at Steady State | 5.46 ± 2.01 | 5.09 ± 2.53 |
Dose proportionality of trough plasma concentrations at steady state is explored by using the power model that described the functional relationship between the dose and plasma concentration
| ng/mL | Pramipexole Extended Release Group (PPX ER) |
|---|---|
| Dose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment | 1.0375 ± 0.0177 |
UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms. Least square means and standard errors presented are from ANCOVA with factors treatment and covariate baseline.
| UPDRS scores on a scale | From PPX ER to PPX ER | From PPX IR to PPX ER |
|---|---|---|
| Change From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase) | -2.2 ± 0.6 | -0.2 ± 0.6 |
Percentage of patients with no worsening of UPDRS Parts II+III Total Score by more than 15% from week 12 to week 16 (Open-label: Dose Adjustment Phase)
| percentage of participants | From PPX ER to PPX ER | From PPX IR to PPX ER |
|---|---|---|
| Percentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase) | 78.4 | 83.0 |
Clinical Global Impression of Improvement (CGI-I) at week 16 compared to patient's CGI-I status at week 12. CGI-I scores ranging from '1' (very much improved) to '7' (very much worse)
| percentage of participants | From PPX ER to PPX ER | From PPX IR to PPX ER |
|---|---|---|
| Very much improved | 0.0 | 1.9 |
| Much improved | 8.0 | 5.7 |
| Minimally improved | 48.0 | 35.8 |
| No change | 34.0 | 50.9 |
| Minimally worse | 10.0 | 5.7 |
Patient Global Impression of Improvement (PGI-I) at week 16 compared to patient's PGI-I status at week 12. PGI-I scores ranging from '1' (very much better) to '7' (very much worse).
| percentage of participants | From PPX ER to PPX ER | From PPX IR to PPX ER |
|---|---|---|
| Very much better | 2.0 | 3.8 |
| Much better | 14.0 | 11.3 |
| A little better | 36.0 | 35.8 |
| No change | 36.0 | 39.6 |
| A little worse | 12.0 | 9.4 |
UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| UPDRS scores on a scale | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase) | -15.2 ± 11.1 |
Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse
| percentage of participants | Pramipexole ER: Open-Label Phase |
|---|---|
| UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase) | 92.0 |
Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
| Percentage of off-time | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in Percentage Off-time (Open-label: Maintenance Phase) | -11.6 ± 22.1 |
Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase) | 11.9 ± 21.1 |
Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase) | -0.1 ± 5.7 |
Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase) | 11.8 ± 21.6 |
Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase) | -0.2 ± 2.8 |
The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.
| mg per day | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase) | 10.3 ± 62.0 |
UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood
| UPDRS scores on a scale | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase) | -0.3 ± 1.5 |
UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.
| UPDRS scores on a scale | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase) | -3.4 ± 4.2 |
UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms
| UPDRS scores on a scale | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase) | -11.9 ± 8.2 |
UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy
| UPDRS scores on a scale | Pramipexole ER: Open-Label Phase |
|---|---|
| Change From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase) | -0.6 ± 1.6 |
Collected over From the first dose of trial medication onwards through the observational phase (64 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole Extended Release Group (PPX ER) | — | 12/56 (21.4%) | 52/56 (92.9%) |
| Pramipexole Immediate Release Group (PPX IR) | — | 10/56 (17.9%) | 49/56 (87.5%) |
| Event | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 2/56 | 0/56 |
| Parkinson's diseaseNervous system disorders | 1/56 | 2/56 |
| Inguinal herniaGastrointestinal disorders | 2/56 | 0/56 |
| Posture abnormalMusculoskeletal and connective tissue disorders | 1/56 | 2/56 |
| PneumoniaInfections and infestations | 0/56 | 1/56 |
| PyelonephritisInfections and infestations | 1/56 | 0/56 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/56 | 0/56 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/56 | 0/56 |
| DelusionPsychiatric disorders | 1/56 | 1/56 |
| Hallucination, visualPsychiatric disorders | 1/56 | 1/56 |
| Event | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) |
|---|---|---|
| SomnolenceNervous system disorders | 21/56 | 20/56 |
| NasopharyngitisInfections and infestations | 18/56 | 18/56 |
| ConstipationGastrointestinal disorders | 7/56 | 12/56 |
| Back painMusculoskeletal and connective tissue disorders | 8/56 | 11/56 |
| NauseaGastrointestinal disorders | 8/56 | 10/56 |
| FallInjury, poisoning and procedural complications | 7/56 | 10/56 |
| DyskinesiaNervous system disorders | 9/56 | 4/56 |
| DizzinessNervous system disorders | 8/56 | 4/56 |
| Hallucination, visualPsychiatric disorders | 7/56 | 7/56 |
| Orthostatic hypotensionVascular disorders | 7/56 | 5/56 |
| Age, Continuous(years) | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) | Total |
|---|---|---|---|
| Mean | 68.8 ± 8.0 | 66.1 ± 7.5 | 67.5 ± 7.8 |
| Sex: Female, Male(Participants) | Pramipexole Extended Release Group (PPX ER) | Pramipexole Immediate Release Group (PPX IR) | Total |
|---|---|---|---|
| Female | 35 | 35 | 70 |
| Male | 21 | 21 | 42 |
The record gives a start of Nov 2007 and a primary completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole